Logo

BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer

Share this

BioNTech Entered into a Research Collaboration with Medigene to Boost T Cell Receptor Immunotherapies Against Cancer

Shots:

  • Medigene to receive $29.37M up front & research funding & will be eligible to receive development, regulatory & commercial milestone along with tiered deferred option fees & royalties. BioNTech gets an exclusive option to acquire additional TCRs in Medigene’s discovery pipeline & get the license to Medigene’s PD1-41BB switch receptor & precision pairing technologies
  • BioNTech will hold exclusive commercialization rights globally on all TCR therapies & will lead the global development of the product
  • The collaboration will use BioNTech’s immunotherapy capabilities & Medigene’s TCR discovery platform to develop TCR immunotherapies for multiple solid tumor targets selected by BioNTech

 Ref: Globe Newswire | Image: Bloomberg

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions